Aleglitazar Clinical Trials
Roche Halts Trials on Diabetes Drug Aleglitazar
“…The independent Data and Safety Monitoring Board (DSMB) has recommended to halt the trial due to safety signals and lack of efficacy,” F. Hoffman-La Roche media release.
Thomas J. Henry is currently investigating adverse effects caused by Roche’s diabetes drug Aleglitazar. Clinical trials for the drug were halted after it was found to cause heart problems, kidney problems, and an increased risk of bone fractures. The drug had been tested on over 7,000 participants with Type 2 Diabetes before the Data and Safety Monitoring Board called for the trials to be stopped.
DIABETES DRUG ALEGLITAZAR TESTED IN CLINICAL TRIAL
- Aleglitazar, an experimental drug treatment, was being developed by Roche.
- Aleglitazar was used in a 6-arm, double blind clinical trial for the treatment of Type 2 Diabetes.
- Drugs similar to aleglitazar have been scrapped from development by other companies over the years due to heart risks.
- F. Hoffman-La Roche Ltd., creator of Aleglitazar, has had two previous failures (taspoglutide and dalcetrapid) in their attempts to move out of oncology (cancer treatments).
ADVERSE EVENTS AND SIDE EFFECTS REPORTED IN ALEGLITAZAR TRIAL PATIENTS
- Heart problems
- Kidney problems
- Bone fractures
- Gastrointestinal disorders
- Increased creatine phosphokinase in the blood
- Upper respiratory tract infection
ALEGLITAZAR CLINICAL TRIAL LOCATIONS (U.S.)
Click here for a full list of U.S. and international trial locations.
- Phoenix, Arizona
- Beverly Hills, California
- Palm Spring, California
- San Diego, California
- Chiefland, Florida
- Hollywood, Florida
- West Palm Beach, Florida
- Augusta, Georgia
- Idaho Falls, Idaho
- Chicago, Illinois
- Baton Rouge, Louisiana
- Baltimore, Maryland
- Olive Branch, Mississippi
- Hamilton, New Jersey
- New Hyde Park, New York
- Johnson City, Tennessee
- Spokane, Washington